Search for content, post, videos

Japan Grants Patent to Nordic Nanovector

The Japan Patent Office (JPO) has issued patent no. 5646652 entitled “NOVEL RADIOIMMUNOCONJUGATES AND USES THEREOF” to Nordic Nanovector. The issued claims cover Nordic Nanovector’s proprietary radioimmunotherapy (RIT) technology, including the company`s lead product candidate Betalutin™, a new targeted agent for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL).